Randomised evaluation of COVID-19 therapy (RECOVERY)

Primary objective: To provide reliable estimates of the effect of study treatments on all-cause mortality at 28 days after first randomisation. 

Type of study: Interventional; Phase III, treatment

Treatment tested: Lopinavir/Ritonavir, low dose corticosteroids, Hydroxychloroquine, Azithromycin, Convalescent plasma and Tocilizumab

Country: UK   

Sample size: 12,000

Study participants: Hospitalized, SARS-CoV-2 Infection (clinically suspected or laboratory confirmed) with no medical history that might in the opinion of the attending clinician, put the patient at significant risk if she/he were to participate to the trial

Study status: Recruiting

Principal investigator

More information

Last updated: June 2020

Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.

We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.